Application of 2023 FIGO staging system for 2019 FIGO stage I endometrial cancer DOI Creative Commons
Peng‐Hui Wang, Tricia Dewi Anggraeni, Tofan Widya Utami

et al.

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(2), P. 210 - 212

Published: March 1, 2025

Language: Английский

Current genetic test for ovarian cancer DOI Creative Commons

Szu‐Ting Yang,

Penghui Wang

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(1), P. 8 - 10

Published: Jan. 1, 2025

Language: Английский

Citations

2
Expression of female hormone receptor and prognosis of cervical cancer: Does any relationship exist? DOI Creative Commons

Yiu‐Tai Li,

Szu‐Ting Yang,

Peng‐Hui Wang

et al.

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(1), P. 6 - 7

Published: Jan. 1, 2025

Language: Английский

Citations

0
Menopause part I: Vasomotor symptoms (I) DOI Creative Commons
Peng‐Hui Wang,

Szu‐Ting Yang,

Wen-Hsun Chang

et al.

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(2), P. 230 - 238

Published: March 1, 2025

Menopause, an aged process due to loss of permanent ovarian function (mainly decreased production estrogen) without another pathological or physiological cause becomes one the most health issues in world. Vasomotor symptoms (VMS) is a hallmark menopause, occurring up 80 % women experiencing and persisting for over seven years with significant negative impacts on physical, psychological, social, overall wellbeing. Conventionally, menopause hormone therapy (MHT) considered effective therapeutic opinion many based fact as "deficiency estrogen"; however, ratio benefits risk highly debated always concern. Therefore, non-MHT agent focusing underlying pathophysiology VMS, such hypothalamus-pituitary-ovary axis becoming attractive. Based this concept, hypothalamus neural construct containing Kisspeptin (Kp) neurons median pre-optic area (POA) Kp-neurokinin B (NKB)-dynorphin (DYN) (KNDy neurons) infundibular nucleus identified thermoregulatory circultry involve normal reproduction menopause-associated VMS. The neurokinin 3 receptor (NK3R) antagonists applied VMS are enthusiasm big success. Fezolinetant best breakthroughs. Recent three randomized clinical trials (RCTs), including SKYLIGHT 1,2, 4 confirmed safety efficacy treating moderate-to-severe women. By contrast, MONGLIGHT RCTs East Asia population seemed controversial effect treatment, but there no doubt that issue also satisfied, contributing need more validate its diverse population. current review will summary recent advance new landscape management particularly focus fezolinetant product.

Language: Английский

Citations

0
Application of 2023 FIGO staging system for 2019 FIGO stage I endometrial cancer DOI Creative Commons
Peng‐Hui Wang, Tricia Dewi Anggraeni, Tofan Widya Utami

et al.

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(2), P. 210 - 212

Published: March 1, 2025

Language: Английский

Citations

0